Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly’s FY2025 momentum remains the headline: revenue rose 44% to nearly $65.2B and net income roughly doubled to ~$20.6B, with free cash flow near $9B and a debt-to-equity ratio around 1.6x. The article projects Lilly’s growth to accelerate in 2026 (revenue up to ~$85.2B and net income near ~$31B) led by GLP-1 demand, despite regulatory pricing pressure from the Inflation Reduction Act. By contrast, Teva reported FY2025 revenue of ~$17.3B (+~4% YoY) and net income of ~$1.4B (net margin ~8.2%) with higher leverage (debt-to-equity ~2.2x) and lower forward valuation (forward P/E 16.4x vs Lilly’s 33.1x), positioning Teva as a cheaper, more leveraged value alternative.

Analysis

LLY remains the cleaner quality compounder, but the setup is more about preserving a premium than expanding it. At a 30+x forward multiple, the stock only keeps compounding if metabolic franchise growth stays ahead of payer pushback and any supply normalization does not force discounts; the market is paying for a multi-year platform, not just one or two quarters of good execution.

TEVA is the opposite: the equity can rerate faster than fundamentals if debt reduction and biosimilar mix improve, but it is still a leverage story with limited operating cushion. The cleaner relative loser is VTRS, where generic price erosion leaves less room for a self-help narrative; by contrast, MCK/COR/CAH get volume uplift from more scripts but not enough margin leverage to matter unless utilization accelerates materially.

The contrarian miss is that consensus may be underpricing how quickly LLY can de-rate on any reimbursement or pricing scare, while overpricing how "cheap" TEVA is if the balance sheet or litigation path stumbles. For the next 1-3 months, this is mostly a multiple and sentiment trade; over 6-18 months, the real test is whether LLY can keep layering pipeline optionality and whether TEVA can turn biosimilars into durable free-cash-flow conversion rather than just headline revenue.

Key Decisions for Investors

• Long LLY on a 3-5% pullback into earnings or regulatory noise; 6-12 month thesis is premium persistence, but trim if payer/reimbursement commentary starts to slow obesity-growth assumptions.
• Pair trade: long LLY / short VTRS for a 3-6 month relative-value expression of patent-protected growth versus generic price erosion; thesis breaks if VTRS shows sustained biosimilar margin expansion or LLY loses pricing power.
• Avoid chasing TEVA as an outright long until the market sees cleaner debt paydown and FCF conversion; if bought at all, treat it as a catalyst-driven watch item, not a core compounder.
• Use MCK or COR only as secondary beneficiaries of higher GLP-1 utilization; they are volume pass-through winners, so upside is modest and should be expressed only if script growth accelerates meaningfully.
• If LLY sells off on any IRA or supply-chain headline without a guidance cut, consider adding rather than fading the move; if management revises 2026 growth lower, the multiple can compress quickly.